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Seeking Genomic Knowledge:
The Case for Clinical Restraint†
Wylie Burke,* Susan Brown Trinidad,**
and Ellen Wright Clayton***

Genome sequencing technology provides new and promising tests for clinical practice,
including whole genome sequencing, which measures an individual’s complete DNA
sequence, and whole exome sequencing, which measures the DNA for all genes coding
for proteins. These technologies make it possible to test for multiple genes in a single test,
which increases the efficiency of genetic testing. However, they can also produce large
amounts of information that cannot be interpreted or is of limited clinical utility. This
additional information could be distracting for patients and clinicians, and contribute to
unnecessary healthcare costs. The potential for genomic sequencing to improve care will
be context-dependent, varying for different patients and clinical settings. This Article
argues that a disciplined approach is needed, incorporating research to assess when and
how genomic information can improve clinical outcomes, practice guidelines that direct
optimal uses of genomic sequencing, and efforts to limit the production of genomic
information unrelated to the clinical needs of the patient. Without this approach, genomic
testing could add to current unsustainable healthcare costs and prove unaffordable in the
long run.

† This Article is dedicated to the memory and scholarship of Elinor Ostrom, who inspired this
work and many others during her long and impactful career.
* Professor and Chair of Bioethics and Humanities at the University of Washington. Dr. Burke
received her doctorate in genetics and a medical degree from the University of Washington.
** Research Scientist in the Department of Bioethics and Humanities at the University of
Washington. Ms. Trinidad holds a master’s degree from the Interdisciplinary Program in Health and
Humanities at Michigan State University.
*** Professor of Pediatrics, Professor of Law, and Co-Founder of the Center for Biomedical
ethics and Society at Vanderbilt University. Dr. Clayton received her law degree from Yale Law
School and her medical degree from Harvard Medical School.
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Introduction
Over the past two decades, genome science has offered a growing
array of tests that increase diagnostic accuracy and guide clinical
1
management for an increasing number of disorders. Conventional genetic
tests look for specific mutations that are known to cause a given condition.
More dramatic advances are now available in the forms of whole genome
2
sequencing (“WGS”) and whole exome sequencing (“WES”). Both WGS
and WES provide a comprehensive assessment of genetic variation across
the human genome. WGS measures variation in an individual’s entire
DNA, while WES measures variation only in the portions of the DNA that
3
code for proteins. WGS and WES increase efficiency by providing
information about multiple genetic conditions and risks in a single test.
However, WGS and WES also generate unprecedented amounts of
information, much of it extraneous to the clinical encounter or difficult to
4
interpret.
Genome sequencing tests are poised to enter clinical practice at a
challenging time for healthcare in the United States. Medical costs are
rising at unsustainable rates and the system is performing poorly. Services
5
are inefficient, of variable quality, and inequitably distributed. The United

1. See generally Geoffrey S. Ginsburg & Huntington F. Willard, Genomic and Personalized
Medicine: Foundations and Applications, 154 Translational Res. 277 (2009); Teri A. Manolio et al.,
Implementing Genomic Medicine in the Clinic: The Future is Here, 15 Genetics in Med. 1, 3 (2013).
2. See Manolio, supra note 1, at 3; see also Bryce A. Schuler et al., Using Whole Exome Sequencing
to Walk from Clinical Practice to Research and Back Again, 127 Circulation 968, 968 (2013).
3. See generally Manolio, supra note 1; Schuler, supra note 2.
4. See generally Isaac S. Kohane et al., Taxonomizing, Sizing, and Overcoming the Incidentalome,
14 Genetics in Med. 399 (2012).
5. Comm. on Quality of Health Care in Am., Inst. of Med., Crossing the Quality Chasm: A
New Health System for the 21st Century 1–3 (2001).
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States spends far more on medical care compared to other developed
6
countries, yet adoption of evidence-based care is slow and uneven. At the
same time, overly rapid adoption of new technology leads to both patient
7
harm and wasted resources.
Key measures of population health, such as life expectancy and
8
infant mortality, fall far behind those of other developed countries. The
problem is worse for certain populations because of profound healthcare
9
disparities in the United States. Indicating an impending crisis, costs of
the Medicare program began exceeding revenue in 2008; deficits are
projected to increase steadily over the next two decades, leading to the
10
exhaustion of reserves by 2024. The same funding issues are being
experienced at the state level, where the rising expenses of healthcare are
11
reducing funds available for other public expenditures. These rising costs
threaten the national economy, and they will only grow as implementation
of the Patient Protection and Affordable Care Act provides access to
health insurance for many millions of Americans who have previously
12
lacked health insurance.
Therefore, a critical question for genomics is whether it will add to
the problems of the current United States healthcare system or ameliorate
them. This Article argues that the outcome will be determined in large
part by how clinicians and healthcare systems approach the critical process
of developing a standard of care for genomic medicine.

I. The Promise
Genetic science has improved the practice of medical genetics by
offering systematic assessment of genes that are known to be associated
13
with particular disorders. By replacing piecemeal testing with a
comprehensive assessment of virtually all genes, genome sequencing can
14
generate more complete results more quickly. The same gains may
apply in the rapidly developing field of pharmacogenomics—the use of
genetic information to select the safest and most effective therapy for a

6. See generally Inst. of Med., Best Care at Lower Cost: The Path to Continuously
Learning Health Care in America 1 (2011).
7. See id. at 2.
8. Haidong Wang et al., Age-Specific and Sex-Specific Mortality in 187 Countries, 1970–2010: A
Systematic Analysis for the Global Burden of Disease Study 2010, 380 Lancet 2071, at 2082, 2086 (2012).
9. See Comm. on Quality of Health Care in Am., supra note 5, at 1.
10. See Stephen K. Heffler et al., Ctrs. for Medicare & Medicaid Servs., The Long-Term
Projection Assumptions for Medicare and Aggregate National Health Expenditures 22–23
(2012).
11. See, e.g., Massachusetts State Budget, Mass. Budget & Pol’y Ctr., http://www.massbudget.
org/browser/index.php (last visited July 30, 2013).
12. Patient Protection and Affordable Care Act of 2010, Pub. L. No. 111-48, 124 Stat. 119.
13. See generally Ginsburg, supra note 1, Manolio, supra note 2.
14. Id.
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15

particular patient. This approach can also help clinicians to identify
genetic causes of rare clinical findings that have eluded conventional
16
testing. Other benefits are also possible, particularly in cancer
17
treatment. Genetic testing already helps to assess an individual’s risk for
cancer, and genomic studies of tumor tissue can provide prognostic
18
information and help guide chemotherapy. Recent studies suggest that a
full genomic evaluation of a tumor may enhance these benefits and
19
potentially identify new therapeutic options for patients.
Many of these applications are still under development, and the scope
of resulting healthcare improvements is difficult to estimate. Nevertheless,
there are clear indicators that genome sequencing can generate reduced
costs by increasing testing efficiency, and improved outcomes by
20
improving use of drug therapies and targeted treatment and prevention.
Among the remaining uncertainties are whether WES—a less expensive
approach than WGS—can provide the information clinicians seek, and
whether WGS will yield additional clinically important information over
time. Either approach poses difficult questions about the interpretation
and reporting of sequence data.

II. The Challenge
Although the comprehensive sweep of genome sequencing is
attractive for the reasons outlined above, it entails daunting challenges in
information management, education, and communication. In addition to
addressing the results generated for the clinical situation that prompted
testing—for example, assessment of genes associated with an inherited
susceptibility to cancer—clinicians will need to decide whether or when
to pursue other information that genome sequencing could provide. Such
other information can include: (1) the potential discovery of a wide range
of rare genetic conditions, some treatable and some not, (2) information
about carrier status for many genetic diseases, (3) information of varying
reliability and strength about propensities for drug response and common

15. Kathleen M. Giacomini et al., Pharamcogenomics and Patient Care: One Size Does Not Fit
All, Sci. Translational Med., Sept. 2012, at 1.
16. See, e.g., Schuler, supra note 2, at 968–70.
17. See generally Ginsburg, supra note 1; Manolio, supra note 2.
18. Ginsburg, supra note 1, at 281–82.
19. See generally Ken Dutton-Regester & Nicholas K. Hayward, Reviewing the Somatic Genetics
of Melanoma: From Current to Future Analytical Approaches, 25 Pigment Cell & Melanoma Res. 144
(2012); Levi. A Garraway & José Baselga, Whole-Genome Sequencing and Cancer Therapy: Is Too
Much Ever Enough?, Cancer Discovery, Sept. 2012, at 766.
20. See generally Giacomini, supra note 15; Ginsburg, supra note 1; Schildcrout et al., Optimizing
Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping, 92 Clinical
Pharmacology & Therapeutics 235 (2012).
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diseases, and (4) a large amount of information that is not readily
21
interpretable.
While many medical tests and procedures involve the potential for
incidental findings—such as an unexpected mass on a chest x-ray or an
unexpected skin abnormality on a physical examination—the scope of
potential findings from genome-scale tests is unprecedented. WGS and
WES can generate information from an estimated 20,000 to 25,000 genes,
and if WGS is used, information about the non-coding regions of the DNA
sequence that may or may not have functional significance is generated as
22
well. While only a small number of genes will produce abnormal results
in any given individual, these results could number in the dozens or even
hundreds, depending on how “abnormal” or “reportable” is defined.
For example, the first detailed analysis of a human genome from a
healthy adult found over 2.5 million “single nucleotide polymorphisms”
23
(points where the DNA sequence differed from a reference sequence).
Many of these variants could represent neutral or benign changes, but
even when focusing on the most clinically relevant genes, the investigative
team identified several gene mutations associated with rare genetic
diseases (most indicating carrier status), sixty-three variants associated
with drug response (along with several other potentially important drugrelated variants that had not previously been described), and genetic
changes that could increase the estimated risk for eight of fifty-five
24
common diseases.
Another study involving the genomes from nine individuals found
an average of 136 genes per genome with deleterious mutations; in 40%
of the genes, deleterious mutations were homozygous, which led to the
25
expectation that they would have clinical effects. All nine genomes had
rare or novel variants that were difficult to interpret. This study also
noted a substantial potential for false positive results—that is, results that
26
erroneously suggested increased risk. Both of the studies described
above also noted that insufficient evidence and errors in existing
27
databases made interpretation difficult. The problem is made more
difficult by the rapid pace of genomic research: the implications of
specific findings may change over short periods of time.

21. See generally Jonathan S. Berg et al., Deploying Whole Genome Sequencing in Clinical
Practice and Public Health: Meeting the Challenge One Bin at a Time, 13 Genetics in Med. 499 (2011);
Kohane et al., supra note 4.
22. See A Brief Guide to Genomics, Nat’l Human Genome Research Inst. (Oct. 19, 2011),
http://www.genome.gov/18016863; Euan A. Ashley et al., Clinical Assessment Incorporating a Personal
Genome, 375 Lancet 1525, 1526 (2010).
23. Ashley et al., supra note 22, at 1526–27.
24. Id. at 1530, 1532–33.
25. Kohane et al., supra note 4, at 400.
26. Id.
27. See Ashley et al., supra note 22, at 1533; Kohane et al., supra note 4, at 401.
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In this setting, clinicians and policymakers (including professional
societies and other expert groups charged with developing practice
guidelines) face two distinct difficulties. The first is determining the
threshold for disclosure of results from WGS or WES testing. A stringent
approach would report only those findings that are relevant to the purpose
of testing—for example, only those findings relevant to inherited cancer
risk. But some argue that the “extraneous” information yielded by WGS
and WES could have substantial clinical or personal utility; even if it was
not sought, it could—and should—be offered to patients.
Johnston and colleagues evaluated, for example, the results of WES
28
in 572 research participants. The analysis focused on thirty-seven genes
29
known to be associated with inherited risk of cancer. A total of
454 variants were found that differed from the reference sequence; of
these, eight were determined to be deleterious based on published
literature and four were found in individuals who did not meet current
30
family history criteria for genetic testing. This example illustrates the
potential benefits of genomic screening but also the substantial analytic
effort and threshold choices—including which genes to evaluate—that are
raised by genome sequencing. Efforts are under way to define result
categories in order to facilitate decisionmaking about which results to
31
report.
The second challenge is determining what kind of information or
counseling should be provided to patients before and after testing.
Counseling needs will be highly dependent on decisions about what
information is disclosed. Current standards of practice call for pre-test
counseling with a particular emphasis on the need to ensure that patients
give informed consent before receiving information about two categories
of genomic information: (1) test results reporting on the presence of an
inherited disease for which no treatment is available, such as Huntington
disease, and (2) test results related to detecting a carrier state, which may
32
indicate a risk of having children with a genetic disorder.
After testing arises the challenge of how to explain the limitations
and ambiguities of genomic information. Even when findings suggest the
presence of a genetic disease, the implications may be difficult to predict
with certainty. For example, analysis of James Watson’s genome indicated
33
that he is homozygous for a deleterious mutation in the ERCC6 gene.
28. Jennifer J. Johnston et al., Secondary Variants in Individuals Undergoing Exome Sequencing:
Screening of 572 Individual Identifies High-Penetrance Mutations in Cancer-Susceptibility Genes,
91 Am. J. Hum. Genetics 97, 97 (2012).
29. Id. at 99.
30. Id. at 97, 100, 104.
31. See generally Berg, supra note 21.
32. Id.
33. See, e.g., Edison T. Liu, HUGO President Reports from the HUGO Symposium on Genomics
and Ethics, Law and Society 2009, HUGO Matters: The Official Blog of the Human Genome Org.
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This genotype is expected to cause Cockayne syndrome, a genetic
condition associated with short stature, premature aging, and cognitive
34
impairment. Yet none these phenotypic features are evident in Watson,
35
a Nobel Laureate and co-discoverer of DNA structure. The reason for
this discrepancy is not known, but it is likely either that the test failed to
detect a normal copy of ERCC6 or that modifying factors (genetic or
non-genetic) were present that prevented the usual clinical effect of the
36
Cockayne genotype. In fact, the manifestations of many monogenic
37
diseases can be highly variable, so caution is encouraged in predicting
the clinical effects of findings in single genes in asymptomatic individuals.
Uncertainties are far greater for gene variants associated with
38
common diseases like diabetes, common cancers, and heart disease. The
uncertainties are due in part to the evolving science: information on
genetic associations for common disease is still being accumulated. Little is
known about many variants, and errors in assignment of risk are present in
39
current databases. In addition, risk prediction for common diseases is
inherently limited due to the multifactorial nature of these conditions,
which are influenced not only by genetics, but also by lifestyle, childhood
40
environment, and other exposures. Even the genetic component is
complex because risk for most common diseases is associated with changes
in many different genes, each associated with very small increments of
41
risk.

(Nov. 2, 2009), http://www.hugo-international.org/blog/?p=86.
34. David Wheeler et al., The Complete Genome of an Individual by Massively Parallel DNA
Sequencing, 452 Nature 872, 874 (2008).
35. See, e.g., Liu, supra note 33.
36. See id.
37. Katrina M. Dipple & Edward R. B. McCabe, Phenotypes of Patients with “Simple” Mendelian
Disorders Are Complex Traits: Thresholds, Modifiers, and Systems Dynamics, 66 Am. J. Hum.
Genetics 1729, 1731, 1733 (2000). See generally Ernest Beutler, Discrepancies Between Genotype and
Phenotype in Hematology: An Important Frontier, 98 Blood 2597 (2001).
38. See generally Nilanjan Chatterjee et al., Projecting the Performance of Risk Prediction Based
on Polygenic Analyses of Genome-Wide Association Studies, 45 Nature Genetics 400 (2013); Muin
Khoury et al., How Can Polygenic Inheritance Be Used in Population Screening for Common
Diseases?, Genetics in Med., Feb. 2013, at 1; Kohane et al., supra note 4, at 399, 403.
39. Callum J. Bell et al., Carrier Testing for Severe Childhood Recessive Diseases by Next-Generation
Sequencing, Sci. Translational Med., Jan. 2011, at 1, 11; Kohane et al., supra note 4. See generally Misha
Angrist, Only Connect: Personal Genomics and the Future of American Medicine, 14 Molecular
Diagnosis & Therapy 67, 68–69 (2010) (discussing the need for further interpretation of variations).
40. See generally Abby G. Ershow, Environmental Influences on Development of Type 2 Diabetes
and Obesity: Challenges in Personalizing Prevention and Management, 3 J. Diabetes Sci. & Tech. 727
(2009); J.J. Reilly & J. Kelly, Long-Term Impact of Overweight and Obesity in Childhood and
Adolescence on Morbidity and Premature Mortality in Adulthood: Systematic Review, 35 Int’l J. Obesity
891 (2011).
41. Khoury, supra note 38, at 2.
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III. Genomic Screening?
Although the science is still rapidly evolving, many experts anticipate
substantial benefits from the use of genomic sequencing as a screening
42
tool. These experts emphasize that identification of previously
unsuspected genetic disorders or risk states in healthy individuals could
43
allow for early initiation of treatment and prevention efforts. In addition
to rare individuals with substantial inherited risk, such as the cancer risks
44
found in a research study of WES, genome sequencing would identify
many individuals with genetic susceptibilities to many common diseases.
Although the risks identified in this way would generally be modest—
typically no more than twofold above average—some experts believe that
such information could be used to motivate healthy patient behaviors and
to inform clinicians about options for medical screening and early
45
treatment.
Genomic screening is further envisioned by some as a component of
46
“precision medicine,” a new approach envisioned for healthcare in which
a menu of molecular tools would be used to provide early identification
and intervention in disease processes. The science behind this approach is
often referred to as “omics,” capturing the measurement of body proteins
(“proteomics”), other body metabolites (“metabolomics”), and gene
47
expression profiles, in addition to genome sequencing. The vision of
precision medicine adds to optimism about genomic screening.
IV. Perspective of Clinicians and Healthcare Systems
The vision of genomic screening and the potential benefits of
precision medicine must be viewed in the context of healthcare realities.
Much of healthcare still fits into a traditional model of returning a person
in ill health to normal function: examples include casting to heal a broken
arm, surgery to repair a hernia, medications to resolve anginal pain or
asthma symptoms, and chemotherapy to eradicate a cancer. Healthcare
also involves the co-management by clinician and patient of chronic
diseases, with therapeutic care aimed at improving function and quality of
life and palliative care to reduce pain and suffering for individuals with
terminal illnesses.

42. See generally Angrist, supra note 39; Manolio, supra note 1; Schildcrout, supra note 20.
43. See Should Healthy People Have Their Genomes Sequenced at This Time?, Wall St. J. (Feb. 13,
2013, 5:03 PM), http://online.wsj.com/article/SB10000872396390443884104577645783975993656.html;
Angrist, supra note 39.
44. See, e.g., Johnston, supra note 28, at 100–02.
45. Should Healthy People Have Their Genomes Sequenced at This Time?, supra note 43.
46. See generally Comm. on a Framework for Developing a New Taxonomy of Disease, Nat’l
Res. Council of the Nat’l Acads., Toward Precision Medicine: Building a Knowledge Network
for Biomedical Research and a New Taxonomy of Disease (2011).
47. Monya Baker, Big Biology: The ‘Omes Puzzle, 494 Nature 416, 418–19 (2013).
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At the heart of the genomic screening vision, however, is the
concept that health outcomes can be improved substantially by a shift in
focus toward preventive care. Many preventive measures are now routine
parts of medical practice, including many types of cancer screening,
vaccinations, and treatment for conditions such as hypertension and
48
hypercholesterolemia. Preventive care has led to substantial benefits:
one compelling example is the virtual absence of several childhood
diseases among immunized populations; another is the greater than 90%
drop in cervical cancer rates among women receiving regular Pap
49
screenings. Any interventions with this kind of potential represent an
important gain for the healthcare system.
Unfortunately, preventive care can sometimes harm people. All
medical interventions carry the potential for harm, and there is particular
concern about this possibility when interventions are used in healthy
50
people to avert future disease. Several examples illustrate the problem.
Newborn screening for neuroblastoma became possible in the 1980s, and
was embraced in some locations; however, studies comparing outcomes
among screened and unscreened populations revealed no change in
disease mortality and identified several instances of infants harmed by
51
treatment. These outcomes were due to limitations in the identification
of risk: Testing missed some infants with serious disease (false negatives)
and found others who had benign forms of the condition (false positives).
In a more recent example, screening for prostate cancer by testing for the
prostate-specific antigen (“PSA”) has become increasingly controversial
because of evidence that it performs poorly as a screening test, leading to
52
many unnecessary and debilitating interventions in healthy men. The
U.S. Preventive Services Task Force has recently suggested discontinuing
53
this screening program. In other examples, screening has led to adverse
labeling, as in the case for children who experienced morbidities solely as
54
a result of the identification of benign heart murmurs. Even in programs
for which benefits are well established, some previously healthy individuals

48. See Recommendations, U.S. Preventative Servs. Task Force (Dec. 2010), http://www.
uspreventiveservicestaskforce.org/recommendations.htm.
49. Adriana Bermudez, Can We Do the Same in the Developing World?, 99 Gynecologic
Oncology S192, S192–93 (2005).
50. Charles M. Kilo & Eric B. Larson, Exploring the Harmful Effects of Health Care, 302 J. Am.
Med. Ass’n 89, 89 (2009).
51. William G. Woods et al., A Population-Based Study of the Usefulness of Screening for
Neuroblastoma, 348 Lancet 1682, 1682 (1996); S. Barrette et al., Treatment Complications in Children
Diagnosed with Neuroblastoma During a Screening Program, 24 J. Clinical Oncology 1542 (2006).
52. See, e.g., Virgina A. Moyer, Screening for Prostate Cancer: U.S. Preventive Services Task Force
Recommendation Statement, 120 Annals Internal Med. 120 (2012).
53. Id.
54. See generally Abraham B. Bergman & Stanley J. Stamm, The Morbidity of Cardiac Nondisease
in Schoolchildren, 276 New Eng. J. Med. 1008 (1967).
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will experience harm; for example, cholesterol-lowering treatment can
55
cause myopathy leading to renal failure.
These examples underscore a key principle of preventive care:
Programs should be based on strong evidence that the overall
improvement in health outcome substantially outweighs the potential for
complications and harm. A cornerstone of effective prevention programs
is the accurate identification of people at risk, for whom prevention
efforts are worth the potential adverse consequences. Critical questions
include how accurately screening procedures identify candidates for
further intervention and whether available interventions can prevent
disease safely and effectively. A related concern is opportunity cost. By
its nature, preventive care involves interventions in large groups of
healthy people—in some cases, such as immunizations, the entire
population. Healthcare systems must consider which screening and
preventive efforts are worth the cost, given that resources could
otherwise be directed toward other healthcare needs.
Some genetic tests offer clear benefits in this regard—for example,
targeted preventive care can be offered to women with a high risk of
breast and ovarian cancer identified by the presence of deleterious
mutations in the breast cancer susceptibility (“BRCA”) genes—but most
56
risk identified by genomic screening will be more modest and contingent.
The hope is that that identification of risk or early disease will provide
opportunities to intervene early, as the natural history of disease processes
is better understood at the molecular level. But how early and what
interventions should be used? For many disorders, the benefits and risks of
early intervention are not yet known. As has been seen with PSA
screening, treatment risks could loom large for those who would never
have developed disease or whose disease would not have progressed. For
other interventions, such as promoting a healthy lifestyle, targeted
approaches pose the potential harms of creating stigma and decreasing the
incentive for all to take part.
Even when risk assessment is helpful for targeting prevention,
genomics will not always be the best way to identify people at risk. For
example, identifying people in a social network for group-based
interventions might provide a better strategy to enhance smoking
cessation, increase physical activity, or encourage healthy eating. Making
wise decisions about population health strategies will require challenging

55. See generally F.L Mastaglia & M. Needham, Update on Toxic Myopathies, 12 Current
Neurology & Neuroscience Rep. 54 (2012); Willaim S. David et al., Case Records of the Massachusetts
General Hospital: Case 7–2012—A 79-Year-Old Man with Pain and Weakness in the Legs, 366 New Eng.
J. Med. 944 (2012).
56. See Nicholas J. Roberts et al., The Predictive Capacity of Personal Genome Sequencing, Sci.
Translational Med., May 2012, at 58–59; Steven A. Narod, BRCA Mutations in the Management of
Breast Cancer: The State of the Art, 7 Nature Rev. Clinical Oncology 702, 702–03 (2010).
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efforts to assess the relative value of political measures (such as
population-level interventions to improve access to education and safe
neighborhoods), behavioral measures (such as innovative approaches to
smoking cessation or early childhood physical education and nutrition),
and medical measures (such as medical screening and drug treatment for
individuals with increased risk for chronic conditions). In assessing
medical measures, much of the knowledge we currently deploy in
healthcare is likely to remain useful in the era of genomics. At the same
time, we will need to continue to evaluate new technologies to determine
whether they do or do not provide new benefits.
These considerations are relevant to the use of WGS or WES because
they have important implications for identification and disclosure of
findings that are unrelated to the clinical question that prompted testing.
The pursuit of such additional findings represents a screening process, in
that it seeks risk information unrelated to the patient’s presenting
complaint. The worry for the healthcare system is that comprehensive
disclosure of results from genome sequencing would introduce risk
information into the healthcare process that is distracting and of
57
uncertain value. Time that otherwise might be spent discussing the
patient’s concerns or well-established preventive care (such as colon
cancer screening) might instead be used to talk through the implications
of gene variants that are associated with small increases in risk for a
variety of diseases. Clinicians might also need to spend time making sure
that genomic tests do not lead to false reassurance—for example,
explaining to a patient that the lack of a BRCA mutation does not mean
that she has a lower than average risk of developing breast cancer. The
worry, in other words, is that information from genome sequencing could
distort the use of healthcare resources on a grand scale.

V. Developing a Standard of Care
No practice standard currently exists for genomic medicine. Typically,
views concerning the appropriate use of a new technology evolve as it
comes into use. Payers are likely to decline payment in the absence of
definitive data indicating a healthcare benefit. Over time, as clinicians
gain experience and outcome data become available, a practice standard
emerges. Formal practice guidelines are helpful in defining the practice
standard, unless conflicting recommendations emerge from different
groups. Payer policies tend to reflect the emerging consensus.
The lack of a practice standard for genomic medicine represents an
opportunity for reflection about the role of genomic information in
achieving the goals of healthcare. In the words of John Eisenberg,
technology “is rarely inherently good or bad, always or never useful. The
57. See generally Ashley et al., supra note 22; Kohane et al., supra note 4.
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challenge is to evaluate when in the course of an illness it is effective, for
whom it will enhance outcomes, and how it should be implemented or
58
interpreted.” At present, the benefits of WGS and WES are evident in
only a few narrowly defined clinical circumstances: where patients are
undergoing a genetic work-up that involves assessment of multiple
different genes, and where a patient’s clinical presentation indicates a
genetic disease that has evaded diagnosis by usual measures. Other
potential benefits are still under investigation, including the value of
genomic sequencing of cancers. However, even when there is a clear
benefit, it derives from only a small portion of the genomic information
obtained through sequencing. An urgent question for healthcare systems
is to determine how these benefits can be realized without overwhelming
the healthcare system with distracting information.
A logical approach to managing this risk would be to limit the test
results that enter clinical care, even when the testing process generates a
full genomic sequence. Arguably, this approach is consistent with routine
approaches in laboratory medicine that limit reporting to the specific
results that were ordered, even when the testing platform generates
additional data. Whether clinical use of WGS and WES might be linked to
research efforts aimed at a better understanding of genomic information is
a separate and important matter. However, prudent use of healthcare
resources calls for limiting the time clinical laboratories spend on sequence
analysis and the time clinicians spend explaining genomic test results.
However, patient preferences represent a potential challenge to this
approach.

VI. The Role of Patient Demand
A move toward patient empowerment in healthcare has developed
over several decades, and represents an important effort to improve
59
quality of care and patient satisfaction. Groundbreaking lawsuits filed in
the 1980s and 1990s established the right of patients to refuse care that
60
was recommended or instituted by their physicians. The right to refuse
61
care is now recognized as nearly unlimited. In rare circumstances,
treatment may be imposed as a public health measure (as in treatment of

58. John M. Eisenberg, Ten Lessons for Evidence-Based Technology Assessment, 282 J. Am. Med.
Ass’n 1865, 1868 (1999).
59. Delos M. Cosgrove et al., Ten Strategies to Lower Costs, Improve Quality, and Engage
Patients: the View from Leading Health System CEOs, 32 Health Aff. 321, 321 (2013).
60. See Cruzan v. Dir., Mo. Dep’t of Health, 497 U.S. 261, 278–79 (1990) (“The principle that a
competent person has a constitutionally protected liberty interest in refusing unwanted medical
treatment may be inferred from our prior decisions.”).
61. See Washington v. Glucksberg, 521 U.S. 702, 720 (1997) (“We have also assumed, and
strongly suggested, that the Due Process Clause protects the traditional right to refuse unwanted
lifesaving medical treatment.”).
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tuberculosis), but a competent adult is otherwise free to refuse any care.
Patient empowerment goes beyond the basic right to refuse care and
includes acknowledging the legitimacy of a patient’s access to medical
records and laboratory results, and a patient’s right to choose among the
63
array of options available to meet her healthcare needs. Engaging
patients in their health management and offering them treatment choices
may be an important mechanism to ensure both better care and lower
64
costs. In this context, some experts have suggested that genomics will be
a powerful tool for patient empowerment, enabling patients to take more
65
control of their own healthcare. This view is problematic for two
reasons: First, it overestimates the potential for genomic risk information
to generate improved health outcomes, and second, it erroneously implies
that patient empowerment includes the right to demand medical tests that
lack clinical utility.
It is likely that only a small percentage of patients have yet considered
whether they would like to have access to the information generated by
sequencing their genome. Yet among those who have (undoubtedly a
biased sample), strong preferences have been expressed for receiving all
66
possible information from genome sequencing. For example, science
writer Virginia Hughes complains about a paternalistic emphasis on
protecting patients from potentially troubling genomic information (such
as gene variants associated with a future risk of Alzheimer disease).
Instead of accommodating patient preferences, “the medical community
has neglected to talk about more pressing logistical problems: (1) How to
ask people ahead of time what, precisely, they want to know (and don’t
want to know), and (2) How to improve the medical system so doctors can
67
follow through on those wishes.”
Her unquestioning assumption that the health system should
“follow through” on patient wishes presumes that access to the full array
68
of results is solely a matter of patient preference. This view ignores the

62. See id. at 279, 284; Canterbury v. Spence, 464 F.2d 772, 780 (D.C. Cir. 1972). See generally
Ruth R. Faden & Tom L. Beauchamp, A History and Theory of Informed Consent (1986); Law in
Pub. Health Prac. 274 (Richard A. Goodman et al. eds., 2d ed. 2007).
63. Health Insurance Portability and Accountability Act of 1996, Pub. L. 104-191, 110 Stat. 1936
(codified as amended in scattered sections of 42 U.S.C.).
64. David Veroff et al., Enhanced Support for Shared Decision Making Reduced Costs of Care for
Patients with Preference-Sensitive Conditions, 32 Health Aff. 285, 291 (2013).
65. Leroy Hood & Stephen H. Friend, Predictive, Personalized, Preventive, Participatory (P4)
Cancer Medicine, 8 Nature Rev. Clinical Oncology 184, 186 (2011).
66. Virginia Hughes, It’s Time to Stop Obsessing About the Dangers of Genetic Information,
Slate (Jan. 7, 2013, 3:51 PM), http://www.slate.com/articles/health_and_science/medical_examiner/
2013/01/ethics_of_genetic_information_whole_genome_sequencing_is_here_and_we_need.html;
Misha Angrist, You Never Call, You Never Write: Why Return of ‘Omic’ Results to Research
Participants Is Both a Good Idea and a Moral Imperative, 8 Personalized Med. 651 (2011).
67. Hughes, supra note 66.
68. Id.
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opportunity costs to the healthcare system of facilitating access to
genomic information that is not needed for healthcare. It also conflicts
with clinicians’ ethical obligation to use their competence—and the
shared medical resources that they control—to benefit the patient’s
69
health. Yet to the extent that such views are incorporated into practice
standards for genomic testing, they could generate legal obligations for
70
broad disclosure.

VII. What Should Guide Practice Standards for
Genome-Scale Testing?
Decisions about when new medical technologies are ready for
“prime time” involve asking whether the technology confers benefit and
whether it is safe and effective. Often, full consideration of these issues
includes the circumstances under which the technology should be used
71
and the potential for harm. Most controversies—such as PSA testing,
72
mammography for women under fifty years of age, and spiral computed
73
tomography for lung cancer screening —center around the evidence
available and the certainty with which benefits and harms can be
estimated. Practice standards and healthcare payer policies often involve
explicit definitions of the circumstances under which the technology is
appropriate. For example, guidelines of the American Cancer Society
specify criteria for the use of magnetic resonance imaging (“MRI”) for
breast cancer screening, indicating that MRI should be used only for
women who are at increased risk—measured by genetic testing, specific
74
clinical diagnoses, or specific family history. Similarly, massage therapy
may be covered by some insurers in some states, but its use is typically
limited to a small number of treatments in the context of an injury,
despite the fact that some patients might prefer greater access.
In the case of genome sequencing, there are clear indicators that
testing can assist in certain difficult diagnostic situations and can be an
efficient method for concurrent assessment of multiple genes in medical
genetic work-ups. The indications for the uses of WGS and WES may
grow over time as research reveals new potential uses for genomic
information. However, the large volume of information potentially
69. See generally Troy Brennan et al., Medical Professionalism in the New Millennium: A
Physician Charter, 136 Ann. Internal Med. 243 (2012).
70. See generally Ellen Wright Clayton & Amy L. McGuire, The Legal Risks of Returning Results
of Genomics Research, 14 Genetics in Med. 473 (2012).
71. See generally Moyer, supra note 53.
72. See generally Summer Sawyer Allen, & Sandhya Pruthi, The Mammography Controversy:
When Should You Screen?, 60 J. Fam. Prac. 524 (2011).
73. See generally Peter B. Bach et al., Benefits and Harms of CT Screening for Lung Cancer: A
Systematic Review, 307 J. Am. Med. Ass’n 2418 (2012).
74. Debbie Saslow et al., American Cancer Society Guidelines for Breast Screening with MRI as an
Adjunct to Mammography, 57 CA: Cancer J. for Clinicians 75, 83 (2007).
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generated by such testing poses risks to individuals and the healthcare
system. Practice guidelines for the use of WGS and WES must consider
the potential for iatrogenic harm from work-ups spurred by incidental
findings, as well as the potential for false reassurance if the lack of
genomic risk information is misinterpreted as removing risk for common
diseases. It is equally important for practice guidelines to consider the
potential impact of WGS and WES on healthcare resources. In the
context of unsustainable increases in the cost of care, there is an urgent
need to consider the cost-effectiveness of new technologies, asking
critically whether they improve upon existing interventions. Clinicians,
who are increasingly time-pressured by the array of evidence-based
interventions available to them, are focused on making the most of their
time with patients and need practice guidelines that enable them to do
75
so.

Conclusion
Can genomics deliver what the healthcare system urgently needs:
gains in health outcome at reduced cost? This Article suggests that this
outcome is possible with disciplined leadership from genetics professionals
and healthcare policymakers. A responsible practice standard for WGS
and WES will limit disclosure of incidental findings. Choices are
available within this approach. Disclosure could be limited to the results
relevant to the clinical question for which testing was done, or with the
patient’s informed consent, analysis could extend to evaluation of a small
set of genes associated with conditions for which well-defined clinical
prevention measures are available, such as genes associated with
significant cancer risk. Despite patients’ arguments for the “right” to
their genome sequence, testing done within the healthcare system should
be focused on healthcare needs. Failure to maintain this discipline opens
a path toward wasteful and harmful testing practices that are likely,
ultimately, to result in the rejection of genomic solutions by hard-pressed
healthcare systems.

75. See Kimberly S.H. Yarnall et al., Family Physicians as Team Leaders: “Time” to Share the
Care, Preventing Chronic Disease: Pub. Health Res., Prac., & Pol’y, Apr. 2009, at A59.
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